AI-Powered Blood Test for Leprosy: Revolutionizing Early Detection

Breakthrough research in Brazil develops highly accurate test to identify leprosy exposure and early-stage disease

Apr. 11, 2026 at 7:07pm

Got story updates? Submit your updates here. ›

Researchers at the University of São Paulo have developed an AI-assisted blood test that can detect leprosy in its early stages with unprecedented accuracy. The test identifies antibodies to the Mce1A antigen, allowing for the identification of individuals exposed to the leprosy bacillus even before symptoms appear. With 100% sensitivity when combined with AI analysis, this breakthrough has significant implications for improving treatment outcomes and reducing disease transmission in Brazil and other high-burden countries.

Why it matters

Leprosy remains a major public health challenge, particularly in low- and middle-income countries. The ability to detect the disease in its early stages, when treatment is most effective, is crucial for controlling transmission and improving patient prognosis. Traditional laboratory tests often fail to identify leprosy in the initial phase, when symptoms are subtle. This new AI-powered blood test represents a significant advancement that could revolutionize leprosy screening and management.

The details

The new blood test developed by researchers at the University of São Paulo detects antibodies to the Mce1A antigen, which is associated with exposure to the leprosy-causing bacteria. By identifying individuals who have been exposed to the pathogen, even before the onset of clinical symptoms, the test allows for earlier intervention and treatment. When combined with an artificial intelligence tool, the test achieved 100% sensitivity, successfully flagging all suspected cases that were later confirmed through in-person consultations. This level of accuracy is a major improvement over traditional laboratory tests, which often fail to detect leprosy in its early stages.

  • The study was conducted in 2025 and the findings were published in April 2026.

The players

Filipe Lima

A biomedical scientist and lead author of the study on the AI-powered leprosy blood test.

University of São Paulo

The Brazilian research institution where the breakthrough leprosy detection technology was developed.

Got photos? Submit your photos here. ›

What they’re saying

“Traditional laboratory tests often fail to identify leprosy in its early stages, when symptoms are subtle and treatment is more effective. This new blood test can detect exposure to the leprosy bacillus before the onset of clinical symptoms.”

— Filipe Lima, Biomedical Scientist

What’s next

The next step is to advance the validation of these tools for large-scale use and incorporate them into Brazil's national public health system, the SUS. Additionally, the study aims to increase the specificity of the Mce1A marker, which could lead to an even more sensitive and accurate test.

The takeaway

The development of an AI-assisted blood test for early leprosy detection is a significant advancement in medical diagnostics. By facilitating early detection and improving treatment outcomes, this breakthrough has the potential to revolutionize the way we approach this ancient disease and reduce its burden, particularly in high-prevalence countries like Brazil.